To our knowledge, this is the first study to examine the prognostic impact of both PD-1 and its ligand PD-L1 in the same prostate cancer cohort, and the first to explore prognostic effects of PD-1+ lymphocytes in prostate cancer altogether. This evidence concerns the gene PDCD1 and prostate carcinoma.